MedDataX Logo

Online Referral and Intervention to Prevent Adolescent and Young Adult Suicide

NCT04642157 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2025-06-27

No results posted yet for this study

Summary

ORIAS is a randomized controlled trial designed to study the efficacy of the ELIOS system in reducing suicidality in the AYA, reinforcing their motivation to seek help and making them access to care.

As ELIOS would be the first suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media, ORIAS was designed to address the challenge of deciding whether this innovation is worth adding to the current national and international prevention arsenal. While randomized control trials are crucially lacking in the field of suicide prevention, especially on the Internet, the high-level evidence that ORIAS is expected to bring could have a decisive influence on how the French prevention strategies will seize the social media.

Conditions

  • Suicide

Interventions

OTHER

ELIOS

ELIOS is a suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media. This includes * A systematic initial contact with an ELIOS web-clinician * Systematic recontacts by the ELIOS web-clinicians scheduled at 24h, 72h and/or 7 days, depending on the participants' level of suicide risk * The opportunity to spontaneously contact the ELIOS system and get in contact with a web-clinician

OTHER

other resources contacts

Three types of resources will be suggested via the ELIOS website: * The General Practitioner (GP) * The closest medico-psychologic center (CMP) * The emergency services The order of presentation of the resource contacts will depend on the participants' intensity of suicidal ideation.

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV

  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Charles-Edouard Notredame, MD · CHU Lille

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-13
Primary Completion
2026-07-13
Completion
2026-07-13

Countries

  • France

Study Locations

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04642157 on ClinicalTrials.gov